Table 3.
Factors contributing to non-adherence for OADs.
| Non-adherent (PRR > 0.2) n = 110 (47.0) | Adherent (PRR ≤ 0.2) n = 124 (53.0) | Total n = 234 (100) | Odds ratio (95% CI) | P value | C-statistic | |
|---|---|---|---|---|---|---|
| PATIENT FACTORS | ||||||
| Age, n (%) | ||||||
| <60 | 22 (20.0) | 15 (12.1) | 37 (15.8) | 1.38 (0.58–3.34) | 0.471 | 0.680 |
| 60–74 | 50 (45.5) | 59 (47.6) | 109 (46.6) | 0.99 (0.52–1.89) | 0.985 | – |
| ≥75 | 38 (34.5) | 50 (40.3) | 88 (37.6) | 1.00 | NA | – |
| Sex, n (%) | ||||||
| Male | 71 (64.5) | 71 (57.3) | 142 (60.7) | 1.00 | NA | 0.680 |
| Female | 39 (35.5) | 53 (42.7) | 92 (39.3) | 0.81 (0.46–1.41) | 0.447 | – |
| Patient copayment, n (%) | ||||||
| 0% | 7 (6.4) | 6 (4.8) | 13 (5.6) | 1.13 (0.32–4.07) | 0.849 | 0.675 |
| 10% | 43 (39.1) | 56 (45.2) | 99 (42.3) | 0.88 (0.49–1.61) | 0.687 | – |
| 30% | 60 (54.5) | 62 (50.0) | 122 (52.1) | 1.00 | NA | – |
| PRESCRIPTION FACTORS | ||||||
| Number of concurrent OADs, n (%) | ||||||
| 1 | 48 (43.6) | 42 (33.9) | 90 (38.5) | 1.00 | NA | 0.673 |
| 2 | 40 (36.4) | 47 (37.9) | 87 (37.2) | 0.69 (0.37–1.28) | 0.235 | – |
| 3–5 | 22 (20.0) | 35 (28.2) | 57 (24.4) | 0.57 (0.28–1.15) | 0.117 | – |
| Prescription days, n (%) | ||||||
| ≤ 30 | 83 (75.5) | 90 (72.6) | 173 (73.9) | 1.00 | NA | 0.664 |
| >30 | 27 (24.5) | 34 (27.4) | 61 (26.1) | 0.89 (0.48–1.65) | 0.709 | – |
| Single-dose packaging, n (%) | ||||||
| Yes | 12 (10.9) | 31 (25.0) | 43 (18.4) | 0.58 (0.25–1.31) | 0.191 | 0.674 |
| No | 98 (89.1) | 93 (75.0) | 191 (81.6) | 1.00 | NA | – |
The odds ratio (OR) and 95% confidence interval (CI) were calculated to predict the factors associated with non-adherence (PRR > 20%). Logistic regression models were adjusted for the total number of concurrent drugs, number of concurrent OADs, OAD prescription days, and nonuse of single-dose packaging.
Adherence status: number (%).
OADs, oral antidiabetic drugs; PRR, prescription reduction ratio.